SCHEMBL6287965

SCHEMBL6287965

CC(C)(C)OC(=O)C[C@H](NC(=O)Cc1c[nH]c2ccccc12)C(=O)Nc1ccc(C(c2ccc(NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)Cc3c[nH]c4ccccc34)cc2)c2ccc(NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)Cc3c[nH]c4ccccc34)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
TP53 P04637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.46
HDAC8 Q9BY41 5/20 0.45
HDAC3 O15379 4/20 0.45
HDAC4 P56524 4/20 0.45
HDAC1 Q13547 4/20 0.45
HDAC7 Q8WUI4 4/20 0.45
HDAC2 Q92769 4/20 0.45
HDAC10 Q969S8 4/20 0.45
HDAC11 Q96DB2 4/20 0.45
HDAC6 Q9UBN7 4/20 0.45
HDAC9 Q9UKV0 4/20 0.45
HDAC5 Q9UQL6 4/20 0.45
TACR1 P25103 1/20 0.45
CTSL P07711 1/20 0.45
CTSS P25774 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7037698 0.92 MAPT (0.55) MAPTSMN1; SMN2TP53L3MBTL1ALDH1A1
SCHEMBL6287655 0.86 HDAC1 (0.50) MAPTSMN1; SMN2ALDH1A1MAPK1HDAC8
SCHEMBL6288043 0.85 HDAC8 (0.49) MAPTSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL6287783 0.84 HDAC8 (0.61) MAPTSMN1; SMN2MAPK1HDAC8HDAC3
SCHEMBL6287685 0.84 HDAC1 (0.52) MAPTSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL6284142 0.81 HDAC1 (0.50) MAPTSMN1; SMN2MAPK1HDAC8HDAC3
SCHEMBL7038483 0.81 HDAC1 (0.49) MAPTSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL6290992 0.81 HDAC8 (0.54) MAPTSMN1; SMN2MAPK1HDAC8HDAC3
SCHEMBL6287895 0.81 HRH3 (0.53) MAPTSMN1; SMN2L3MBTL1ALDH1A1HDAC8
SCHEMBL6291018 0.81 CTSC (0.48) MAPTSMN1; SMN2L3MBTL1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK MAPT 4866/4885SMN1; SMN2 1648/4885TP53 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.